Catalyst
Slingshot members are tracking this event:
FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole) in treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| TKPYY |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 27, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Dexilant, Solutab, Dexlansoprazole, Proton Pump Inhibitor, Heartburn
